Supriya Lifescience Limited has successfully completed its postal ballot process for the appointment of three independent directors, with shareholders demonstrating overwhelming support for all proposed resolutions. The pharmaceutical company announced the results on April 11, 2026, following the completion of remote e-voting that concluded on April 10, 2026.

Postal Ballot Overview

The postal ballot process was conducted exclusively through remote e-voting, with the voting period spanning from March 11, 2026, at 9:00 a.m. IST to April 10, 2026, at 5:00 p.m. IST. The company had 83,037 shareholders on the record date of February 27, 2026, which served as the cut-off date for voting purposes.

Director Appointments Approved

All three special resolutions for independent director appointments received exceptional shareholder approval, with support rates exceeding 99% across all categories.

Resolution Results

New Board Members

The approved appointments will strengthen the company's board governance:

• Mr. Manish Panchal (DIN: 08431492) has been appointed as Non-Executive Independent Director for a five-year term from February 09, 2026, to February 08, 2031
• Mr. Kothandaraman Hari (DIN: 08901674) has been appointed as Non-Executive Independent Director for the same five-year period
• Dr. Neelam Arora (DIN: 01603068) has been re-appointed for her second term as Non-Executive Independent Director from March 25, 2026, to March 24, 2031

Voting Pattern Analysis

The voting results demonstrated strong support across all shareholder categories. Promoter and Promoter Group shareholders, holding 54,967,825 shares, voted unanimously in favour of all resolutions with 100.00% approval. Public Institutions, with 8,549,572 shares, showed 97.48% approval, while Public Non-Institutions maintained over 99% support for the appointments.

Regulatory Compliance

The postal ballot process was conducted in compliance with Regulation 30 and 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 108 and 110 of the Companies Act, 2013. CS Sanam Umbargikar of DSM & Associates served as the scrutinizer for the voting process, ensuring transparency and regulatory adherence throughout the proceedings. The company also published advertisements in Financial Express and Loksatta newspapers on March 11, 2026, as required under regulatory guidelines.

Supriya lifescience Limited has filed its quarterly compliance certificate with stock exchanges, confirming adherence to SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE Limited and National Stock Exchange of India Limited on April 10, 2026.

Regulatory Compliance Certificate

The certificate was issued by MUFG Intime India Private Limited, formerly Link Intime India Private Limited, which serves as the company's Registrar and Share Transfer Agent. The document, dated April 3, 2026, confirms compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Certificate Confirmation Details

MUFG Intime India Private Limited confirmed that securities received from depository participants for dematerialisation during the quarter were properly processed and confirmed to the depositories. The registrar verified that all securities comprised in the certificates have been listed on stock exchanges where the company's previously issued securities are traded.

The certificate also confirms that security certificates received for dematerialisation were appropriately confirmed or rejected, and the physical certificates were mutilated and cancelled after due verification by the depository participant. The names of the depositories have been substituted in the register of members as registered owners within prescribed timelines.

Company Secretary Filing

Prachi Sathe, Company Secretary and Compliance Officer of Supriya Lifescience Limited, digitally signed and submitted the compliance certificate to the stock exchanges. The filing was completed on April 10, 2026, ensuring timely regulatory compliance.

Corporate Information

Supriya Lifescience Limited operates from its corporate office in Mumbai and maintains manufacturing facilities in Maharashtra. The company is recognized as a Government Recognised Export House and continues to maintain its regulatory compliance obligations across all operational quarters.